{"id":1992,"date":"2024-08-30T12:30:18","date_gmt":"2024-08-30T10:30:18","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=1992"},"modified":"2024-08-30T11:48:50","modified_gmt":"2024-08-30T09:48:50","slug":"year-end-report-july-1-2023-june-30-2024","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/year-end-report-july-1-2023-june-30-2024\/","title":{"rendered":"Year-end report July 1, 2023 &#8211; June 30, 2024"},"content":{"rendered":"<p class=\"p1\"><strong>Summary of year-end report<\/strong><\/p>\n<p class=\"p1\"><strong>Fourth quarter (2024-04-01 \u2013 2024-06-30)<\/strong><\/p>\n<ul>\n<li class=\"p2\">Net sales amounted to SEK 0.0 million (0.0)<\/li>\n<li class=\"p2\">Operating profit amounted to SEK -1.6 million (-1.3)<\/li>\n<li class=\"p2\">Earnings per share* SEK -0.07 (-0.06)<\/li>\n<\/ul>\n<p class=\"p1\"><strong>Full year (2023-07-01 \u2013 2024-06-30)<\/strong><\/p>\n<ul>\n<li class=\"p2\">Net sales amounted to SEK 0.0 million (0.0)<\/li>\n<li class=\"p2\">Operating profit amounted to SEK -5.5 million (-4.9)<\/li>\n<li class=\"p2\">Earnings per share* SEK -0.25 (-0.25)<\/li>\n<li class=\"p2\">Cash and cash equivalents at the end of the financial year amounted to SEK 19.0 (25.2) million<\/li>\n<\/ul>\n<p class=\"p2\"><i>* Before and after dilution. Earnings per share: Profit for the period divided by the average number of<\/i><\/p>\n<p class=\"p2\"><i>shares 18,485,857. For the comparison period, the average number of shares was 18,485,857.<\/i><\/p>\n<p class=\"p2\"><i>Amounts in brackets refer to the corresponding period last year.<\/i><\/p>\n<p class=\"p1\"><strong>Comments from the CEO<\/strong><\/p>\n<p class=\"p2\">On August 12, DexTech Medical announced new positive results from the myeloma study. The Phase<\/p>\n<p class=\"p2\">1 study examines the efficacy of OsteoDex in patients with progressive treatment-resistant multiple<\/p>\n<p class=\"p2\">myeloma (MM). Progressive disease means that the disease progresses and does not respond to<\/p>\n<p class=\"p2\">existing treatment. The first dose group (3mg\/kg) is now ready and the DMC (Data Monitoring<\/p>\n<p class=\"p2\">Committee) has approved the start of dose group 2 (6mg\/kg). DMC assesses all analysis results to<\/p>\n<p class=\"p2\">decide on the next higher dose. No side effects related to OsteoDex have been noted. All patients<\/p>\n<p class=\"p2\">show a decrease in skeletal biomarkers. <b>Three out of four patients have stable disease after<\/b><\/p>\n<p class=\"p2\"><b>completion of treatment (stable = no progression of the disease).<\/b> Patients with stable disease will<\/p>\n<p class=\"p2\">be followed up until new progress according to the approved amendment, which provides information<\/p>\n<p class=\"p2\">on how long the treatment effect lasts.<\/p>\n<p class=\"p2\">The principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology\/HERM,<\/p>\n<p class=\"p2\">Karolinska University Hospital, Huddinge. Biomarkers are analysed at the Central Laboratory,<\/p>\n<p class=\"p2\">Karolinska University Hospital, NKS, Solna. Patients with relapsed\/treatment-resistant disease who<\/p>\n<p class=\"p2\">have received 1\u20135 prior lines of therapy are included. The primary objective is to confirm safety and<\/p>\n<p class=\"p2\">tolerability and as a secondary objective to determine any treatment response. Documentation of<\/p>\n<p class=\"p2\">quality of life will also be done (QoL scores).<\/p>\n<p class=\"p2\">The first patient was treated in December at Karolinska University Hospital in Huddinge. The first test<\/p>\n<p class=\"p2\">results from patient 1 were received on 23 January and show a very strong effect on the marker of<\/p>\n<p class=\"p2\">osteoclasts activity (CTX). The patient has now completed treatment according to the study protocol<\/p>\n<p class=\"p2\">and now has stable disease. Stable disease means that the disease does not progress (slowed<\/p>\n<p class=\"p2\">down). The results are important and indicate that Osteodex can slow relapsed\/treatment-resistant<\/p>\n<p class=\"p3\"><span class=\"s2\">disease.<\/span><\/p>\n<p class=\"p2\">The fact that three out of four patients respond to treatment with the lowest dose exceeds all<\/p>\n<p class=\"p2\">expectations. We look forward with excitement to treatment with higher doses.<\/p>\n<p class=\"p2\"><i>Anders R Holmberg<\/i><\/p>\n<p><a href=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/DexTech-Year-end-report-July-2023-June-2024.pdf\">DexTech &#8211; Year-end report July 2023 &#8211; June 2024<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Summary of year-end report Fourth quarter (2024-04-01 \u2013 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6 million (-1.3) Earnings per share* SEK -0.07 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-1992","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Year-end report July 1, 2023 - June 30, 2024 | DexTech<\/title>\n<meta name=\"description\" content=\"Summary of year-end report Fourth quarter (2024-04-01 \u2013 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Year-end report July 1, 2023 - June 30, 2024 | DexTech\" \/>\n<meta property=\"og:description\" content=\"Summary of year-end report Fourth quarter (2024-04-01 \u2013 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-30T10:30:18+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/\",\"url\":\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/\",\"name\":\"Year-end report July 1, 2023 - June 30, 2024 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2024-08-30T10:30:18+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"Summary of year-end report Fourth quarter (2024-04-01 \u2013 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Year-end report July 1, 2023 &#8211; June 30, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Year-end report July 1, 2023 - June 30, 2024 | DexTech","description":"Summary of year-end report Fourth quarter (2024-04-01 \u2013 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/","og_locale":"en_US","og_type":"article","og_title":"Year-end report July 1, 2023 - June 30, 2024 | DexTech","og_description":"Summary of year-end report Fourth quarter (2024-04-01 \u2013 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6","og_url":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/","og_site_name":"DexTech","article_published_time":"2024-08-30T10:30:18+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/","url":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/","name":"Year-end report July 1, 2023 - June 30, 2024 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2024-08-30T10:30:18+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"Summary of year-end report Fourth quarter (2024-04-01 \u2013 2024-06-30) Net sales amounted to SEK 0.0 million (0.0) Operating profit amounted to SEK -1.6","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/bokslutskommunike-1-juli-2023-30-juni-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"Year-end report July 1, 2023 &#8211; June 30, 2024"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=1992"}],"version-history":[{"count":1,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1992\/revisions"}],"predecessor-version":[{"id":1995,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1992\/revisions\/1995"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=1992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=1992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=1992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}